Jul 08, 2014
Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
Jun 25, 2014
HEMISPHERX BIOPHARMA TO PRESENT DURING THE 2014 BIO INTERNATIONAL CONVENTION JUNE 26
Jun 16, 2014
Hemispherx Announces New Publication with Potential Insight into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
Jun 03, 2014
Hemispherx Announces that the University of Texas Medical Branch Confirms Activity of Alferon® N Against MERS (Middle East Respiratory Syndrome) Virus
May 27, 2014
Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen® Formulations
May 21, 2014
Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
May 14, 2014
Hemispherx Biopharma Formally Collaborates with the Swiss Department of Defense, Civil Protection and Sports to Study Alferon® Against Tamiflu Resistant Influenza Virus Strains
May 09, 2014
HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2014
May 05, 2014
Alferon® N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro
Apr 08, 2014
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen® Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen® Interaction
 1   2     3    4   5 
 <<   <   >   >>